Multi-site Gram-negative Surveillance Initiative
Some types of bacteria are becoming resistant to all or nearly all antibiotics. This means that patients with infections from these bacteria might have few or no treatment options. Three types of these resistant bacteria are carbapenem-resistant Enterobacteriaceae (“CRE”), carbapenem-resistant Acinetobacter and carbapenem-resistant Pseudomonas aeruginosa. Infections due to these organisms occur among patients in healthcare settings, and have high death rates. Data from this tracking project will help scientists understand illness caused by these bacteria, and help shape prevention strategies to contain and prevent the spread of resistant organisms.
Specifically, the EIP MuGSI surveillance project will:
- Determine the extent of CRE, carbapenem-resistant Acinetobacter and carbapenem-resistant Pseudomonas aeruginosa disease in the United States
- Identify people most at risk for illness from these organisms
- Measure trends of disease over time
In addition, the project provides infrastructure that allows future research to be done on these organisms and other Gram-negative bacteria.
The Multi-site Gram-negative Surveillance Initiative or MuGSI is a part of the CDC’s Emerging Infections Program (EIP) Healthcare-Associated Infections Community Interface (HAIC) activity. Through MuGSI, CDC is conducting active population- and laboratory-based surveillance in a defined surveillance catchment for seven carbapenem-resistant organisms: Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Acinetobacter baumannii and Pseudomonas aeruginosa.
Pseudomonas aeruginosa was added to the list of organisms under surveillance for MuGSI in July 2016. This organism was added because it causes an estimated 51,000 healthcare-associated infections, including pneumonia and surgical site, urinary tract, and bloodstream infections, in the United States each year. According to a CDC report, more than 6,000 (13%) of these infections are multidrug-resistant, with roughly 400 deaths per year attributed to these infections.
- To evaluate the population-based incidence of carbapenem resistance among the following organisms: Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Acinetobacter baumannii and Pseudomonas aeruginosa, and to describe changes in incidence over time.
- To better characterize carbapenem-resistant Enterobacteriaceae (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Pseudomonas aeruginosa (CR-PA) cases to understand epidemiologic characteristics and risk factors in cases in the areas under surveillance.
- To describe known resistance mechanisms among a subset of CRE and CR-PA isolates.
U.S. Census web site was accessed on 6/27/2016.
For CRE and CR-PA surveillance, carbapenem resistance is defined as resistance to at least one of the carbapenem antibiotics (doripenem, imipenem, meropenem, or ertapenem (only CRE)). For CRAB surveillance, a case must have an isolate that is nonsusceptible (intermediate or resistant) to at least one carbapenem (excluding ertapenem). The results of the primary antibiotic susceptibility testing methods (e.g. minimum inhibitory concentration (MIC), zone diameter interpretive criteria) used by participating local clinical laboratories are used to classify isolates as susceptible or nonsusceptible/resistant.
The CRE and CRAB case definition requires that the organism is isolated from a normally sterile body site or urine from residents of the surveillance area. For CR-PA surveillance, the case definition requires that CR-PA be isolated from a normally sterile body site, urine, lower respiratory tract specimen (i.e., sputum, bronchoalveolar lavage, tracheal aspirate), or wound.
Case-patient infections are described based on the information obtained through medical record review, and are categorized based on the patient’s location at the time of incident culture collection and/or where the patient was physically located at a defined time point prior to culture collection.
Recurrent and Persistent Cases
If a new culture meeting the case definition is collected more than 30 days after the patient’s initial case-defining positive culture, it will be reported as an incident case and a case report form will be completed. If a culture was collected less than 30 days after the initial positive culture, the case will be considered as having persistent infection and a case report form will not be completed. This occurrence will be considered a “non-incident” case for the MuGSI surveillance program.
Cases are identified based on the local clinical laboratory’s antibiotic susceptibility testing data. Most local clinical laboratories conduct antibiotic testing using an Automated Testing Instrument (ATI). In many clinical laboratories within the surveillance catchment area, culture results meeting the MuGSI case definitions are identified directly from these ATI systems.
Data collection is performed by trained surveillance epidemiologists in each EIP site. For each incident case, medical record review is performed to gather patient demographic characteristics, location of culture collection, types of infections associated with the positive culture, underlying conditions, and healthcare exposures.
Isolates from incident cases are sent to CDC for molecular characterization. Additionally, CDC contributes some MuGSI isolates to the AR Isolate Bank.
Bulens SN, Yi SH, Walters MS, Jacob JT, Bower C, Reno J, Wilson L, Vaeth E, Bamberg W, Janelle SJ, Lynfield R, Vagnone PS, Shaw K, Kainer M, Muleta D, Mounsey J, Dumyati G, Concannon C, Beldavs Z, Cassidy PM, Phipps EC, Kenslow N, Hancock EB, Kallen AJ. Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012-2015. Emerg Infec Dis. 2018 Apr;24(4):727-34. doi: 10.3201/eid2404.171461.
Guh A, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, Wilson LE, Vaeth E, Lynfield R, Shaw KM, Vagnone PM, Bamberg WM, Janelle SJ, Dumyati G, Concannon C, Beldavs Z, Cunningham M, Cassidy PM, Phipp EC, Kenslow N, Travis T, Lonsway D, Rasheed JK, Limbago BM, Kallen AJ. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013. JAMA. 2015 Oct 13;314(14):1479-87. doi: 10.1001/jama.2015.12480.
Chea N, Bulens SN, Kongphet-Tran T, Lynfield R, Shaw KM, Vagnone PS, Kainer MA, Muleta DB, Wilson L, Vaeth E, Dumyati G, Concannon C, Phipps EC, Culbreath K, Janelle SJ, Bamberg WM, Guh AY, Limbago B, Kallen AJ. Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae. Emerg Infect Dis. 2015 Sep;21(9):1611-1615. doi: https://dx.doi.org/10.3201/eid2109.150198.
Reno J, Schenck C, Scott J, Clark LA, Wang YF, Ray S, Vagnone P, Jacob JT. Querying automated antibiotic susceptibility testing instruments: a novel population-based active surveillance method for multidrug-resistant gram-negative bacilli. Infect Control Hosp Epidemiol. 2014 Apr;35(4):336-41. doi: 10.1086/675608.
Shaw KM, Harper JE, Vagnone PS, Lynfield R. Establishing Surveillance for Carbapenem-resistant Enterobacteriaceae in Minnesota, 2012. Infect Control Hosp Epidemiol. 2014 Apr;35(4):451-3. doi: 10.1086/675615.
Pereira EC, Shaw KM, Vagnone PM, Harper JE, Kallen AJ, Limbago BM, Lynfield R. Thirty-day laboratory-based surveillance for carbapenem-resistant Enterobacteriaceae in the Minneapolis-St. Paul metropolitan area. Infect Control Hosp Epidemiol. 2014 Apr;35(4):423-5. doi: 10.1086/675602.
Pfeiffer CD, Cunningham MC, Poissant T, Furuno JP, Townes JM, Leitz A, Thomas A, Buser GL, Arao RF, Beldavs ZG. Establishment of a statewide network for carbapenem-resistant Enterobacteriaceae prevention in a low-incidence region. Infect Control Hosp Epidemiol. 2014 Apr;35(4):356-61. doi: 10.1086/675605.
CDC. Vital signs: Carbapenem-Resistant Enterobacteriaceae. Morb Mortal Wkly Rep. 2013 Mar 5;62(9):1-6.
- Antibiotic/Antimicrobial Resistance
- Get Smart: Know When Antibiotics Work
- Get Smart for Healthcare: Know When Antibiotics Work
- World Health Organization Advisory Group on Integrated Surveillance of Antimicrobial Resistance
- Transatlantic Taskforce on Antimicrobial Resistance
- European Committee on Antimicrobial Susceptibility Testing
- Canadian Integrated Program for Antimicrobial Resistance Surveillance
- Carbapenem-resistant Enterobacteriaceae in Healthcare Settings
- General information about CRE
- Tracking CRE
- Facility Guidance for CRE) November 2015 Update CRE Toolkit
- Page last reviewed: October 18, 2016
- Page last updated: December 13, 2018
- Content source: